2019冠状病毒病的治疗：对非洲抗菌药物耐药性的影响
Treatment of COVID-19: implications for antimicrobial resistance in Africa.
作者信息
Iwu Chinwe Juliana, Jordan Portia, Jaja Ishmael Festus, Iwu Chidozie Declan, Wiysonge Charles Shey
机构信息
Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Department of Livestock and Pasture Sciences, Faculty of Science and Agriculture, University of Fort Hare, Alice 5700, South Africa.
出版信息
Pan Afr Med J. 2020 Jul 20;35(Suppl 2):119. doi: 10.11604/pamj.supp.2020.35.23713. eCollection 2020.
There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to co-infections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.
目前尚无获批用于治疗新冠肺炎的药物产品。然而，目前在许多情况下，抗生素正被用于新冠肺炎患者的治疗，要么用于治疗合并感染，要么用于治疗新冠肺炎本身。在本评论中，我们强调，新冠肺炎患者抗菌药物处方率的上升可能会进一步加重抗菌药物耐药性（AMR）的负担。我们还强调，尽管抗菌药物耐药性是一个全球性威胁，但非洲往往受其影响最为严重。因此，我们呼吁非洲国家不要忽视治疗新冠肺炎对抗菌药物耐药性可能产生的影响，以及在应对疫情的同时需要加倍努力抗击抗菌药物耐药性。
Zotero 插件